Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.255 USD | -8.01% | -6.60% | +11.42% |
09/05 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
08/05 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.42% | 468M | |
+18.25% | 47.02B | |
+48.77% | 41.86B | |
+0.60% | 41.76B | |
-4.27% | 28.8B | |
+11.85% | 26.05B | |
-21.96% | 19.15B | |
+4.00% | 12.55B | |
+28.75% | 12.34B | |
-4.34% | 11.82B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating